GlaxoSmithKline and Yale University have established a new drug discovery research collaboration to design a potential new class of medicines that kill disease-causing proteins.
Under the agreement, a joint research team will work to show that Yale's pioneering work on proteolysis targeting chimeric molecules, or PROTACs, can be turned into future medicine. PROTAC technology guides disease-causing proteins to a cell's "garbage disposal" where they can be destroyed.
Mutant or higher-than normal amounts of these proteins typically drive disease progression in areas such as oncology, inflammation and infections; yet many cannot be tackled by traditional ways of making drugs.
If successful, GlaxoSmithKline will have the right to use this technology for multiple disease-causing proteins across all therapy areas.
For each protein-degrading drug that is discovered and developed, Yale will be eligible for milestone and royalty payments.